Skip to Main Content

Paper Details

Secretome analysis of patient-derived GBM tumor spheres identifies midkine as a potent therapeutic target.
Exp Mol Med
38
2019
GBM, GBM tumor, GBM tumor spheres, GIC, GICs, Glioblastoma, MDK, PCBP4, antitumor, glioma, glioma-initiating cells, midkine, oxygen, patient, patient-derived GBM tumor spheres, primary brain tumor, sphere-forming GICs
Author NameAffiliation
Hyemi ShinInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Sungkyunkwan University
Hyemi ShinSamsung Advanced Institute for Health Science & Technology (SAIHST), Sungkyunkwan University
Jin-Ku LeeAjou University School of Medicine
Zhaoqi LiuColumbia University
Zhaoqi LiuColumbia University
Raul RabadanColumbia University
Raul RabadanColumbia University
Jeongwu LeeLerner Research Institute, Cleveland Clinic
Donggeon KimInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Sungkyunkwan University
Sung Heon KimInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Sungkyunkwan University
Sung Heon KimSungkyunkwan University
Jeong-Woo OhInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Sungkyunkwan University
Jeong-Woo OhSamsung Advanced Institute for Health Science & Technology (SAIHST), Sungkyunkwan University
Doo-Sik KongSamsung Medical Center, Sungkyunkwan University
Doo-Sik KongSamsung Medical Center, Sungkyunkwan University
Jung-Il LeeSamsung Medical Center, Sungkyunkwan University
Jung-Il LeeSamsung Medical Center, Sungkyunkwan University
Ho Jun SeolSamsung Medical Center, Sungkyunkwan University
Ho Jun SeolSamsung Medical Center, Sungkyunkwan University
Jung Won ChoiSamsung Medical Center, Sungkyunkwan University
Hyun Ju KangInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Sungkyunkwan University
Hyun Ju KangAjou University School of Medicine
Do-Hyun NamInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Sungkyunkwan University
Do-Hyun NamSamsung Advanced Institute for Health Science & Technology (SAIHST), Sungkyunkwan University
Do-Hyun NamSamsung Medical Center, Sungkyunkwan University
Do-Hyun NamInstitute for Refractory Cancer Research, Research Institute for Future Medicine, Sungkyunkwan University
Do-Hyun NamSamsung Advanced Institute for Health Science & Technology (SAIHST), Sungkyunkwan University
Do-Hyun NamSamsung Medical Center, Sungkyunkwan University
  • 1 - 28

Datasets

Release 1.2